Structural MRI detects progressive regional brain atrophy and neuroprotective effects in N171-82Q Huntington's disease mouse model

Yong Cheng, Qi Peng, Zhipeng Hou, Manisha Aggarwal, Jiangyang Zhang, Susumu Mori, Christopher A Ross, Wenzhen Duan

Research output: Contribution to journalArticle

Abstract

Huntington's disease (HD) displays progressive striatal atrophy that occurs long before the onset of clinical motor symptoms. As there is no treatment for the disease once overt symptoms appear, it has been suggested that neuroprotective therapy given during this presymptomatic period might slow progression of the disease. This requires biomarkers that can reliably detect early changes and are sensitive to treatment response. In mouse models of HD, structural MRI measures have been shown to detect disease onset. To determine whether such measures could also be suitable biomarkers for following responses to treatment, we used T2-weighted MR imaging combined with automated morphological analyses and characterized changes in regional brain volumes longitudinally in the N171-82Q HD mouse model in a preclinical trial. We report here that N171-82Q HD mice exhibit adult-onset and progressive brain atrophy in the striatum and neocortex as well as in whole brain; the progressive atrophy in striatum and neocortex is positively correlated with motor deficits. Most notably, MRI also detected neuroprotective effects of sertraline treatment, a neuroprotective agent confirmed in our previous studies. Our present studies provide the first evidence that longitudinal structural MRI measures can detect the therapeutic effect in HD mice, suggesting that such measures in brain could be valuable biomarkers in HD clinical trials.

Original languageEnglish (US)
Pages (from-to)1027-1034
Number of pages8
JournalNeuroImage
Volume56
Issue number3
DOIs
StatePublished - Jun 1 2011

Fingerprint

Huntington Disease
Neuroprotective Agents
Atrophy
Brain
Biomarkers
Neocortex
Corpus Striatum
Sertraline
Therapeutic Uses
Disease Progression
Clinical Trials

Keywords

  • Biomarker
  • Brain atrophy
  • Huntington's disease
  • LDDMM
  • MRI
  • SSRI

ASJC Scopus subject areas

  • Cognitive Neuroscience
  • Neurology

Cite this

Structural MRI detects progressive regional brain atrophy and neuroprotective effects in N171-82Q Huntington's disease mouse model. / Cheng, Yong; Peng, Qi; Hou, Zhipeng; Aggarwal, Manisha; Zhang, Jiangyang; Mori, Susumu; Ross, Christopher A; Duan, Wenzhen.

In: NeuroImage, Vol. 56, No. 3, 01.06.2011, p. 1027-1034.

Research output: Contribution to journalArticle

@article{3d0082b099f546ce95a52ed1ce8556ae,
title = "Structural MRI detects progressive regional brain atrophy and neuroprotective effects in N171-82Q Huntington's disease mouse model",
abstract = "Huntington's disease (HD) displays progressive striatal atrophy that occurs long before the onset of clinical motor symptoms. As there is no treatment for the disease once overt symptoms appear, it has been suggested that neuroprotective therapy given during this presymptomatic period might slow progression of the disease. This requires biomarkers that can reliably detect early changes and are sensitive to treatment response. In mouse models of HD, structural MRI measures have been shown to detect disease onset. To determine whether such measures could also be suitable biomarkers for following responses to treatment, we used T2-weighted MR imaging combined with automated morphological analyses and characterized changes in regional brain volumes longitudinally in the N171-82Q HD mouse model in a preclinical trial. We report here that N171-82Q HD mice exhibit adult-onset and progressive brain atrophy in the striatum and neocortex as well as in whole brain; the progressive atrophy in striatum and neocortex is positively correlated with motor deficits. Most notably, MRI also detected neuroprotective effects of sertraline treatment, a neuroprotective agent confirmed in our previous studies. Our present studies provide the first evidence that longitudinal structural MRI measures can detect the therapeutic effect in HD mice, suggesting that such measures in brain could be valuable biomarkers in HD clinical trials.",
keywords = "Biomarker, Brain atrophy, Huntington's disease, LDDMM, MRI, SSRI",
author = "Yong Cheng and Qi Peng and Zhipeng Hou and Manisha Aggarwal and Jiangyang Zhang and Susumu Mori and Ross, {Christopher A} and Wenzhen Duan",
year = "2011",
month = "6",
day = "1",
doi = "10.1016/j.neuroimage.2011.02.022",
language = "English (US)",
volume = "56",
pages = "1027--1034",
journal = "NeuroImage",
issn = "1053-8119",
publisher = "Academic Press Inc.",
number = "3",

}

TY - JOUR

T1 - Structural MRI detects progressive regional brain atrophy and neuroprotective effects in N171-82Q Huntington's disease mouse model

AU - Cheng, Yong

AU - Peng, Qi

AU - Hou, Zhipeng

AU - Aggarwal, Manisha

AU - Zhang, Jiangyang

AU - Mori, Susumu

AU - Ross, Christopher A

AU - Duan, Wenzhen

PY - 2011/6/1

Y1 - 2011/6/1

N2 - Huntington's disease (HD) displays progressive striatal atrophy that occurs long before the onset of clinical motor symptoms. As there is no treatment for the disease once overt symptoms appear, it has been suggested that neuroprotective therapy given during this presymptomatic period might slow progression of the disease. This requires biomarkers that can reliably detect early changes and are sensitive to treatment response. In mouse models of HD, structural MRI measures have been shown to detect disease onset. To determine whether such measures could also be suitable biomarkers for following responses to treatment, we used T2-weighted MR imaging combined with automated morphological analyses and characterized changes in regional brain volumes longitudinally in the N171-82Q HD mouse model in a preclinical trial. We report here that N171-82Q HD mice exhibit adult-onset and progressive brain atrophy in the striatum and neocortex as well as in whole brain; the progressive atrophy in striatum and neocortex is positively correlated with motor deficits. Most notably, MRI also detected neuroprotective effects of sertraline treatment, a neuroprotective agent confirmed in our previous studies. Our present studies provide the first evidence that longitudinal structural MRI measures can detect the therapeutic effect in HD mice, suggesting that such measures in brain could be valuable biomarkers in HD clinical trials.

AB - Huntington's disease (HD) displays progressive striatal atrophy that occurs long before the onset of clinical motor symptoms. As there is no treatment for the disease once overt symptoms appear, it has been suggested that neuroprotective therapy given during this presymptomatic period might slow progression of the disease. This requires biomarkers that can reliably detect early changes and are sensitive to treatment response. In mouse models of HD, structural MRI measures have been shown to detect disease onset. To determine whether such measures could also be suitable biomarkers for following responses to treatment, we used T2-weighted MR imaging combined with automated morphological analyses and characterized changes in regional brain volumes longitudinally in the N171-82Q HD mouse model in a preclinical trial. We report here that N171-82Q HD mice exhibit adult-onset and progressive brain atrophy in the striatum and neocortex as well as in whole brain; the progressive atrophy in striatum and neocortex is positively correlated with motor deficits. Most notably, MRI also detected neuroprotective effects of sertraline treatment, a neuroprotective agent confirmed in our previous studies. Our present studies provide the first evidence that longitudinal structural MRI measures can detect the therapeutic effect in HD mice, suggesting that such measures in brain could be valuable biomarkers in HD clinical trials.

KW - Biomarker

KW - Brain atrophy

KW - Huntington's disease

KW - LDDMM

KW - MRI

KW - SSRI

UR - http://www.scopus.com/inward/record.url?scp=79955466394&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955466394&partnerID=8YFLogxK

U2 - 10.1016/j.neuroimage.2011.02.022

DO - 10.1016/j.neuroimage.2011.02.022

M3 - Article

VL - 56

SP - 1027

EP - 1034

JO - NeuroImage

JF - NeuroImage

SN - 1053-8119

IS - 3

ER -